Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GLPG-3667 by Galapagos for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
GLPG-3667 is under clinical development by Galapagos and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData,...
GLPG-3667 by Galapagos for Ulcerative Colitis: Likelihood of Approval
GLPG-3667 is under clinical development by Galapagos and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I...
GLPG-5201 by Galapagos for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GLPG-5201 is under clinical development by Galapagos and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
GLPG-5201 by Galapagos for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GLPG-5201 is under clinical development by Galapagos and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
Filgotinib maleate by Galapagos for Giant Lymph Node Hyperplasia (Castleman's Disease): Likelihood of Approval
Filgotinib maleate is under clinical development by Galapagos and currently in Phase I for Giant Lymph Node Hyperplasia (Castleman's Disease)....